Hemicrania Continua: Disease-Characteristics Research Report

Executive summary

Hemicrania continua (HC) is an uncommon primary headache disorder characterized by continuous, strictly unilateral headache, superimposed exacerbations, and ipsilateral cranial autonomic symptoms and/or agitation during exacerbations. An absolute therapeutic response to indomethacin is part of the International Classification of Headache Disorders, third edition (ICHD-3) case definition. HC belongs to the trigeminal autonomic cephalalgia (TAC) group, although migrainous symptoms are frequent.

The evidence base is small. Most data come from specialist-clinic cohorts, case series, functional imaging studies, and expert reviews rather than population cohorts or randomized trials. No causal gene, validated molecular biomarker, disease-specific omics signature, or accepted animal model has been established. The most important recent clinical development is recognition that structural disorders can closely mimic HC, supporting brain MRI—with contrast and targeted vascular or pituitary imaging when indicated—before labeling a case primary. Experimental treatment development remains difficult: a Phase 2 erenumab study enrolled only two participants and was terminated for recruitment difficulty (NCT04303845 chunk 1).

Table: This compact table summarizes the most actionable disease-knowledge-base facts for hemicrania continua, emphasizing what is established versus where evidence is absent. It is useful for rapid curation of phenotype, mechanism, diagnosis, treatment, and trial annotations.

1. Disease information

Definition and classification

HC is a persistent unilateral headache syndrome first described by Sjaastad and Spierings in 1984. The ICHD-3 definition requires:

1. Unilateral headache present for more than three months, with exacerbations of moderate or greater intensity.
2. During exacerbations, at least one ipsilateral cranial autonomic feature—conjunctival injection or lacrimation, nasal congestion or rhinorrhea, eyelid edema, forehead/facial sweating, miosis or ptosis—or restlessness/agitation or aggravation by movement.
3. An absolute response to therapeutic doses of indomethacin.
4. No better alternative diagnosis.

ICHD-3 recognizes remitting HC, with spontaneous remissions lasting at least 24 hours, and unremitting HC, which is continuously present for at least one year without a remission of 24 hours or longer. Contemporary headache literature continues to emphasize the disorder’s rapid and essentially absolute indomethacin response (lane2024primaryheadachesare pages 7-9).

Identifiers and synonyms

• Preferred name: Hemicrania continua
• Synonyms: continuous hemicrania; HC; chronic continuous unilateral headache responsive to indomethacin
• MeSH: Hemicrania Continua; broader hierarchy includes Headache Disorders/Brain Diseases.
• ICD-10-CM: G44.51, Hemicrania continua.
• ICD-11: classified among trigeminal autonomic cephalalgias; local implementations should verify the current extension code rather than mapping solely from ICD-10-CM.
• Orphanet: ORPHA:157835 is commonly used for hemicrania continua.
• MONDO: a dedicated MONDO concept exists in current ontology releases, but the exact release-specific identifier should be verified during ingestion rather than inferred from name matching.
• OMIM: no established Mendelian disease entry or phenotype-gene relationship.

These are aggregated disease-level classifications, not individual EHR observations. Clinical records constitute patient-level evidence only when documenting laterality, duration, autonomic manifestations, exclusionary investigations, and indomethacin response.

2. Etiology, risk, and protective factors

Primary and secondary HC

Primary HC has no established external or genetic cause. Secondary HC-like headache can accompany pituitary lesions, intracranial tumors, vascular lesions or dissection, venous thrombosis, inflammatory orbital disease, infection, trauma, cervical pathology, and other structural disorders. A clinically perfect indomethacin response does not by itself exclude a secondary cause.

No reproducible causal variant, susceptibility locus, modifier gene, family-based inheritance pattern, founder effect, or gene–environment interaction has been established. Consequently, penetrance, carrier frequency, anticipation, germline mosaicism, and consanguinity are not applicable disease characteristics at present.

Reported temporal associations include head or neck trauma, surgery, and occasionally infection, but these are case-level triggers rather than validated population risk factors. Adult onset is usual, but pediatric and late-life onset occur. Women appear somewhat more frequently represented in many series, although HC lacks the striking female predominance originally presumed. No ethnicity, occupation, toxin, smoking pattern, diet, alcohol exposure, or infectious agent has been shown to alter incidence.

Protective factors

No validated genetic or environmental protective factor exists. Avoiding an individual patient’s exacerbation triggers may reduce symptom burden but is not primary prevention. Indomethacin prevents pain while taken; it does not establish that the underlying tendency has been removed.

3. Phenotypes

The defining phenotype is a continuous side-locked headache, commonly temporal, orbital, supraorbital, frontal, or hemicranial, with exacerbations lasting minutes to days. Pain may extend to the occiput, neck, face, oral cavity, or shoulder. A prospective headache-clinic study cited in a 2024 synthesis found facial pain in 21% of HC cases, demonstrating that pain is not necessarily confined to the orbital or temporal region (lane2024primaryheadachesare pages 9-11).

There is no characteristic blood, urine, CSF, endocrine, or histopathologic abnormality. Quality-of-life impairment arises from continuous pain, unpredictable severe exacerbations, sleep disruption, occupational and social disability, and adverse effects of long-term NSAID therapy. HC-specific EQ-5D, SF-36, or PROMIS reference norms remain poorly developed.

4. Genetic and molecular information

No causal gene, HGNC identifier, OMIM gene association, pathogenic or likely pathogenic variant, recurrent copy-number change, chromosomal abnormality, or recognized somatic mutation is established for HC. Accordingly, there are no disease-specific allele frequencies, ACMG classifications, loss-/gain-of-function mechanisms, modifier genes, or pharmacogenomic recommendations.

No reproducible HC-specific DNA-methylation, histone, chromatin, transcriptomic, proteomic, metabolomic, lipidomic, single-cell, spatial-transcriptomic, or multi-omic signature was identified. Routine WES, WGS, gene panels, CMA, karyotyping, FISH, mitochondrial sequencing, and repeat-expansion testing are therefore not indicated for typical isolated HC. Genetic testing should be driven by an alternative syndromic phenotype or family history.

5. Environmental and lifestyle information

HC is not a toxic, radiation-induced, occupational, nutritional, infectious, or communicable disease. Individual exacerbations may be provoked by physical activity, movement, alcohol, sleep disruption, stress, or other migraine-like triggers, but evidence is observational and inconsistent. There is no validated dose–response relationship and no specific pathogen. Secondary headache following trauma or a structural lesion should be coded as secondary rather than assumed to represent idiopathic HC.

6. Mechanism and pathophysiology

Current systems-neuroscience model

The best-supported model is dysfunction of a distributed trigeminal–autonomic pain network rather than a single molecular defect:

1. Nociceptive afferents from cranial dura, trigeminal territories, and upper cervical roots converge in the trigeminocervical complex (TCC).
2. Ascending pathways project to thalamic, brainstem, periaqueductal gray, and hypothalamic regions, generating persistent unilateral pain and altered descending pain control.
3. Trigeminal activation recruits the superior salivatory nucleus and facial-nerve parasympathetic pathways through the sphenopalatine ganglion, producing lacrimation, conjunctival injection, rhinorrhea, and congestion.
4. Sympathetic dysfunction can generate ptosis or miosis.
5. Superimposed network activation produces painful exacerbations and migrainous symptoms.

A recent neuroanatomical synthesis describes the TCC as fundamental to transmission of nociceptive information from the head and neck and notes its convergence of trigeminal, lower-cranial-nerve, and upper-cervical inputs (lane2024primaryheadachesare pages 9-11, lane2024primaryheadachesare pages 11-12). HC-specific PET studies have reported activation involving the contralateral posterior hypothalamus and ipsilateral dorsal rostral pons/ventrolateral midbrain during pain, with normalization after indomethacin. These findings are associative systems-level observations, not evidence that a single region is the initiating lesion.

Molecular interpretation and limitations

Indomethacin inhibits cyclooxygenase-1 and -2 and prostaglandin synthesis, but ordinary NSAID potency does not explain HC’s uniquely complete response. Proposed actions include modulation of nitric-oxide signaling, cerebral blood flow, and trigeminovascular transmission. No specific receptor, ion channel, enzyme deficiency, protein misfolding, immune mechanism, metabolic defect, neurodegenerative process, or epigenetic lesion has been demonstrated.

Suggested terms include GO:0007218 neuropeptide signaling pathway, GO:0007204 positive regulation of cytosolic calcium ion concentration, GO:0006954 inflammatory response only as broad mechanistic hypotheses, and nociception/pain-perception terms as stronger annotations. Relevant cell labels include trigeminal sensory neuron, parasympathetic neuron, sympathetic neuron, thalamic neuron, hypothalamic neuron, and brainstem neuron. These cell assignments are anatomical inferences, not single-cell evidence.

7. Anatomical structures affected

HC is a functional disorder of the nervous system, not a destructive lesion of the painful scalp, orbit, or face.

• Primary system: central and peripheral nervous system.
• Pain pathways: trigeminal nerve, trigeminal ganglion, spinal trigeminal nucleus, TCC, upper cervical afferents, thalamus, periaqueductal gray, dorsal pons, and hypothalamus.
• Autonomic pathway: superior salivatory nucleus, facial nerve parasympathetic fibers, sphenopalatine ganglion, lacrimal and nasal targets; cervical sympathetic pathways.
• Localization: unilateral orbital, supraorbital, temporal, frontal, facial, parietal, or occipital pain; radiation into neck is possible.
• Lateralization: strict unilateral persistence is diagnostically central.

Suggested UBERON labels are brain, brainstem, pons, midbrain, hypothalamus, thalamus, trigeminal nerve, cervical spinal cord, eye region, face, and scalp. No disease-specific mitochondrion, nucleus, ER, lysosome, or other subcellular compartment is established.

8. Temporal development

Onset is usually in adulthood but ranges from childhood to advanced age. It may be abrupt—with the patient recalling the precise day—or insidious. HC can arise de novo as an unremitting disorder or evolve from a remitting pattern. Remissions may be spontaneous or treatment-associated; relapse commonly follows indomethacin withdrawal, sometimes rapidly.

HC is chronic but not known to be neurodegenerative or biologically progressive. There are no accepted early, intermediate, advanced, or end-stage categories. A marked change in pattern, new neurologic deficit, systemic symptom, onset after age 50, pregnancy/postpartum onset, or new Horner syndrome is a critical window for renewed secondary-cause evaluation.

9. Epidemiology, inheritance, and population

Population prevalence and incidence remain uncertain because few community-based studies exist and diagnosis requires an indomethacin trial. A 2023 systematic review and meta-analysis specifically evaluated clinic-based prevalence and clinical features, underscoring that available estimates are referral-based rather than general-population rates (Al-Khazali et al., Cephalalgia, published January 2023, DOI: https://doi.org/10.1177/03331024221131343).

Across headache-clinic studies, HC generally represents well below 1% to approximately 2% of referred patients, depending on case ascertainment and whether indomethacin response is required. These figures must not be interpreted as population prevalence per 100,000. Incidence per 100,000 person-years is unknown. Both sexes and all reported ethnic groups can be affected; clinic series commonly show a modest female predominance. There is no established geographic endemicity.

HC is sporadic and non-Mendelian based on current evidence. Penetrance, expressivity, carrier frequency, anticipation, founder effects, and prenatal or preimplantation testing are therefore not applicable.

10. Diagnostics

Clinical diagnosis and indomethacin test

The practical diagnostic sequence is:

1. Confirm continuous baseline headache for more than three months.
2. Confirm fixed unilateral localization and exacerbations.
3. Document ipsilateral autonomic manifestations or movement-related agitation.
4. Record migrainous features without misclassifying the continuous baseline as chronic migraine.
5. Exclude structural and vascular causes.
6. Demonstrate complete response to an adequate indomethacin trial.

Oral indomethacin is often begun at 25 mg three times daily and increased every several days to 50 mg three times daily if necessary and medically safe. ICHD-3 notes that adults may initially require at least 150 mg/day and occasionally up to 225 mg/day; lower maintenance doses should be sought after response. Parenteral indomethacin—the historical “indotest”—can provide rapid confirmation where available.

A partial response, intolerance before reaching an adequate dose, poor adherence, or concurrent analgesic overuse does not establish ICHD-3 HC. Conversely, an apparently complete response should not override red flags or abnormal imaging.

Imaging and other tests

Brain MRI with and without gadolinium is recommended at least once in a suspected new HC case. Imaging should scrutinize the pituitary/sellar region, cavernous sinus, orbit, posterior fossa, trigeminal pathway, and upper cervical region. MRA/CTA or venous imaging is added when dissection, aneurysm, fistula, reversible vasoconstriction, or venous thrombosis is plausible. Pituitary hormones, inflammatory markers, lumbar puncture, ophthalmologic examination, or cervical imaging are indication-driven rather than routine.

There is no diagnostic EEG, EMG, biopsy, histopathology, blood biomarker, CSF biomarker, liquid biopsy, or omics test.

Differential diagnosis

• Chronic migraine: may be unilateral and autonomic, but is not usually continuously side-locked and does not respond absolutely to indomethacin.
• New daily persistent headache: abrupt remembered onset and continuous course; phenotype is usually migrainous or tension-type rather than indomethacin-defined.
• Paroxysmal hemicrania: short, frequent attacks with pain-free intervals rather than continuous baseline pain.
• Cluster headache: attacks lasting 15–180 minutes with attack-free intervals, often with circadian/bout periodicity.
• SUNCT/SUNA: seconds-to-minutes neuralgiform attacks.
• Cervicogenic headache/occipital neuralgia: cervical provocation, restricted movement, or neuralgiform occipital distribution.
• Trigeminal neuralgia: brief electric-shock pain in trigeminal distributions.
• Medication-overuse headache: usually bilateral or variable and linked to excessive acute medication.
• Secondary mimics: pituitary/cavernous-sinus disease, tumor, dissection, venous thrombosis, orbital inflammation, infection, and traumatic or cervical lesions.

There is no screening program for asymptomatic people, newborns, carriers, or relatives.

11. Outcome and prognosis

HC is painful and disabling but is not known to shorten life expectancy or cause disease-specific mortality. Five- and ten-year survival metrics are therefore not clinically relevant. When indomethacin is effective and tolerated, pain freedom and restoration of function can be dramatic. Without effective treatment, continuous pain can cause persistent disability, impaired sleep and employment, anxiety/depression, medication overuse, and repeated healthcare utilization.

Long-term morbidity often reflects treatment toxicity: dyspepsia, peptic ulceration or bleeding, renal impairment, fluid retention, hypertension, and cardiovascular risk. Prognosis depends more on accurate diagnosis, exclusion of a secondary lesion, and ability to sustain effective therapy than on age or a molecular biomarker. No validated prognostic biomarker or risk calculator exists.

12. Treatment

Indomethacin

First-line and diagnostic treatment: indomethacin, a nonselective cyclooxygenase inhibitor. Complete response is expected in ICHD-defined disease. Use the lowest effective maintenance dose after control is obtained. Gastroprotection with a proton-pump inhibitor is commonly used when not contraindicated; monitor blood pressure, renal function, blood count where appropriate, gastrointestinal symptoms, edema, and cardiovascular risk.

Suggested annotations: CHEBI/DrugBank concept for indomethacin; NCIt concepts Indomethacin, Cyclooxygenase Inhibitor, and Nonsteroidal Anti-inflammatory Drug.

Alternatives when indomethacin is contraindicated or intolerable

Evidence is chiefly case reports or small open-label series, and none is an equivalent diagnostic substitute:

• COX-2-selective inhibitors such as celecoxib—possible benefit but cardiovascular/renal risks.
• Topiramate or gabapentin—occasionally useful; monitor cognitive, metabolic, teratogenic, or sedating effects as relevant.
• Melatonin—may provide full or partial response or permit dose reduction in selected patients. A treatment-focused report was published in March 2024: Cheung, Oliveira, and Goadsby, Cephalalgia, DOI https://doi.org/10.1177/03331024231226196.
• OnabotulinumtoxinA—reported in small series, especially indomethacin-intolerant cases.
• Greater occipital, supraorbital, or trochlear-region blocks—variable and generally temporary benefit.
• Non-invasive vagus nerve stimulation—limited case-level evidence.
• Occipital nerve stimulation—reserved for highly refractory, specialist-confirmed disease because implantation carries infection, lead migration, revision, and hardware risks.

The French NCT01842763 database collects longitudinal efficacy, quality-of-life, technical, and safety information for occipital nerve stimulation in refractory headache disorders including HC. It is observational, active but not recruiting, and has 246 participants across multiple headache diagnoses; therefore, 246 must not be reported as the HC sample size or as proof of HC-specific efficacy (NCT01842763 chunk 1, NCT01842763 chunk 2).

CGRP-targeted treatment and trials

NCT04303845 evaluated a single 140-mg subcutaneous dose of erenumab in unremitting HC previously or currently completely responsive to indomethacin. The Phase 2 study enrolled only two participants and was terminated because of recruitment difficulty; it cannot support an efficacy estimate (NCT04303845 chunk 1). No gene, cell, RNA, CRISPR, or disease-specific immunotherapy is indicated.

No CPIC or PharmGKB genotype-guided strategy exists for HC treatment.

13. Prevention

There is no established primary prevention because causal risk factors are unknown. Vaccination, environmental remediation, carrier screening, prenatal testing, or public-health screening has no HC-specific role.

Secondary prevention consists of prompt recognition, an adequate indomethacin trial, and appropriate imaging to avoid prolonged misdiagnosis or delayed identification of a structural mimic. Tertiary prevention includes maintaining the lowest effective dose, gastroprotection and toxicity monitoring, controlling medication overuse, treating sleep or mood comorbidity, and reassessing patients whose pattern changes. Lifestyle regularity and avoidance of reproducible personal triggers may reduce exacerbations but do not prevent disease onset.

14. Other species and natural disease

No naturally occurring veterinary counterpart meeting human HC criteria has been validated in dogs, cats, livestock, wildlife, or other species. There is no associated NCBI Taxon, VBO breed term, orthologous causal gene, cross-species susceptibility, transmission, or zoonotic potential. Human HC is neither infectious nor transmissible.

15. Model organisms and experimental systems

No disease-specific knockout, knock-in, transgenic, humanized, chemically induced, iPSC, organoid, or cellular HC model is established. General rodent trigeminovascular, dural stimulation, superior-salivatory-nucleus, and TCC models can investigate nociception or trigeminal–autonomic reflexes, but they do not reproduce the defining clinical combination of continuous unilateral pain and absolute indomethacin responsiveness. There are no HC-specific CRISPR/RNAi screens or validated single-cell reference datasets.

Evidence appraisal and curation cautions

1. Diagnostic evidence is strongest: the characteristic phenotype plus absolute indomethacin response is established by international classification and repeated clinical observation.
2. Epidemiologic certainty is low: specialist-clinic proportions should not be converted into population prevalence or incidence.
3. Mechanistic evidence is intermediate and associative: functional imaging and neuroanatomy support trigeminal–autonomic, brainstem, and hypothalamic network involvement, but no initiating molecular lesion is known. The TCC’s anatomical convergence and ascending nociceptive role are well described, although much of this evidence applies across primary headache disorders rather than uniquely to HC (lane2024primaryheadachesare pages 9-11, lane2024primaryheadachesare pages 11-12).
4. Alternative-treatment evidence is low: most reports are uncontrolled and vulnerable to diagnostic heterogeneity, placebo effects, spontaneous remission, and publication bias.
5. Trial evidence remains insufficient: the erenumab trial’s two-person enrollment cannot establish response rates, while the occipital-stimulation registry combines several headache diagnoses (NCT04303845 chunk 1, NCT01842763 chunk 1).

Selected authoritative references and exact source statements

• Lane R, Davies P. “Primary headaches are a continuum driven by a common process.” Discover Medicine. Published October 2024. DOI: https://doi.org/10.1007/s44337-024-00068-w. The review characterizes the TCC as “fundamental to transmission” of nociceptive information from head and neck structures and discusses the rapid, absolute indomethacin response associated with HC (lane2024primaryheadachesare pages 7-9, lane2024primaryheadachesare pages 11-12).
• Al-Khazali HM et al. “Prevalence and clinical features of hemicrania continua in clinic-based studies: a systematic review and meta-analysis.” Cephalalgia. Published January 2023. DOI: https://doi.org/10.1177/03331024221131343.
• Bahra A. “Paroxysmal hemicrania and hemicrania continua: review on pathophysiology, clinical features and treatment.” Cephalalgia. Published November 2023. DOI: https://doi.org/10.1177/03331024231214239.
• Yildiz Goksel H et al. “The critical role of neuroimaging in hemicrania continua: a systematic review and case series.” Headache. Published May 2024;64:674–684. DOI: https://doi.org/10.1111/head.14728.
• Cittadini E, Goadsby PJ. “Hemicrania continua: a clinical study of 39 patients with diagnostic implications.” Brain. Published July 2010;133:1973–1986. DOI: https://doi.org/10.1093/brain/awq137.
• Prakash S, Patel P. “Hemicrania continua: clinical review, diagnosis and management.” Journal of Pain Research. Published June 2017;10:1493–1509. DOI: https://doi.org/10.2147/JPR.S128472.
• ClinicalTrials.gov. NCT04303845, “Erenumab for Treatment of Hemicrania Continua,” Mayo Clinic; study period August 2021–April 2022; terminated, n=2 (NCT04303845 chunk 1).
• ClinicalTrials.gov. NCT01842763, “French Database of Occipital Nerves Stimulation in the Treatment of Refractory Chronic Headache Disorders”; first posted April 30, 2013; registry status active, not recruiting; mixed-diagnosis enrollment n=246 (NCT01842763 chunk 1).

Important limitation: exact abstract quotations could be supplied only where retrievable source text was available. Several key 2023–2024 articles were identifiable by bibliographic metadata but their full abstracts were not available through the retrieval corpus; wording from those articles has therefore not been presented as a direct quotation.

References

1. (NCT04303845 chunk 1): Rashmi B. Halker Singh MD. Erenumab For Treatment of Hemicrania Continua. Mayo Clinic. 2021. ClinicalTrials.gov Identifier: NCT04303845

2. (lane2024primaryheadachesare pages 7-9): Russell Lane and Paul Davies. Primary headaches are a continuum driven by a common process. Discover Medicine, Oct 2024. URL: https://doi.org/10.1007/s44337-024-00068-w, doi:10.1007/s44337-024-00068-w. This article has 3 citations.

3. (lane2024primaryheadachesare pages 9-11): Russell Lane and Paul Davies. Primary headaches are a continuum driven by a common process. Discover Medicine, Oct 2024. URL: https://doi.org/10.1007/s44337-024-00068-w, doi:10.1007/s44337-024-00068-w. This article has 3 citations.

4. (lane2024primaryheadachesare pages 11-12): Russell Lane and Paul Davies. Primary headaches are a continuum driven by a common process. Discover Medicine, Oct 2024. URL: https://doi.org/10.1007/s44337-024-00068-w, doi:10.1007/s44337-024-00068-w. This article has 3 citations.

5. (NCT01842763 chunk 1): French Database of Occipital Nerves Stimulation in the Treatment of Refractory Chronic Headache Disorders. Centre Hospitalier Universitaire de Nice. 2013. ClinicalTrials.gov Identifier: NCT01842763

6. (NCT01842763 chunk 2): French Database of Occipital Nerves Stimulation in the Treatment of Refractory Chronic Headache Disorders. Centre Hospitalier Universitaire de Nice. 2013. ClinicalTrials.gov Identifier: NCT01842763

Artifacts

• Edison artifact artifact-00

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.